Company intelligence / Profile preview

Hunan Zhaotai Yongren Medical Innovation Co., Ltd.

Changsha, Hunan, Chinaadisinsight.springer.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The company has developed Zeushield Cytotoxic T Lymphocytes (Z-CTLs) which has reached Phase 1 clinical trials for recurrent non-small cell lung cancer in China. Another product, Induced-T cell Like NK cells, has reached Phase 2 clinical trials for neoplasms.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapiesNatural Killer Cell TherapiesGene therapiesImmunotherapiesCytotoxic T Lymphocytes
Industry: Biotech

Drug pipeline

1 asset

zeushield cytotoxic t lymphocytes

Partnerships

Xiangya Hospital Central South University

Beyond the preview

Go deeper on Hunan Zhaotai Yongren Medical Innovation Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hunan Zhaotai Yongren Medical Innovation Co., Ltd..

Explore the full profile